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Abstract
A potential pivotal role for mitochondrial dysfunction in neurodegenerative diseases is gaining increasing acceptance.
Mitochondrial dysfunction leads to a number of deleterious consequences including impaired calcium buffering, generation
of free radicals, activation of the mitochondrial permeability transition and secondary excitotoxicity. Neurodegenerative
diseases of widely disparate genetic etiologies may share mitochondrial dysfunction as a final common pathway. Recent
studies using cybrid cell lines suggest that sporadic Alzheimer’s disease is associated with a deficiency of cytochrome oxidase.
Friedreich’s ataxia is caused by an expanded GAA repeat resulting in dysfunction of frataxin, a nuclear encoded
mitochondrial protein involved in mitochondrial iron transport. This results in increased mitochondrial iron and oxidative
damage. Familial amyotrophic lateral sclerosis is associated with point mutations in superoxide dismutase, which may lead to
increased generation of free radicals and thereby contribute to mitochondrial dysfunction. Huntington’s disease (HD) is
caused by an expanded CAG repeat in an unknown protein termed huntingtin. The means by which this leads to energy
impairment is unclear, however studies in both HD patients and a transgenic mouse model show evidence of bioenergetic
defects. Mitochondrial dysfunction leads to oxidative damage which is well documented in several neurodegenerative
diseases. Therapeutic approaches include methods to buffer intracellular ATP and to scavenge free radicals. ß 1998
Elsevier Science B.V. All rights reserved.
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1. Introduction
Neurodegenerative diseases are a heterogeneous
group of illnesses with distinct clinical phenotypes
and genetic etiologies. Major advances in under-
standing the pathogenesis of these illnesses have
come from molecular genetics. Despite the presence
of genetic defects in widely varying proteins substan-
tial evidence points to mitochondrial dysfunction as
a unifying fundamental mechanism involved in neu-
ronal degeneration. Mitochondrial dysfunction has
widespread deleterious rami¢cations for cellular
function which are discussed in greater detail in other
subsections of this review. In brief mitochondrial
dysfunction leads to impaired energy production, im-
paired cellular calcium bu¡ering, activation of pro-
teases and phospholipases, activation of nitric oxide
synthase, and generation of free radicals. The above
pathways can lead to either apoptotic or necrotic cell
death depending on the severity of the insult.
The present review will focus on four prototypical
neurodegenerative diseases which are associated with
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either nuclear or mitochondrial DNA mutations
which either directly or indirectly lead to mitochon-
drial dysfunction. Recent evidence implicates a cyto-
chrome oxidase de¢ciency in Alzheimer’s disease.
There is a mutation in a nuclear encoded mitochon-
drial protein in Friedreich’s ataxia. In familial amyo-
trophic lateral sclerosis mitochondrial dysfunction
may be a consequence of oxidative damage due to
point mutations in Cu,Zn superoxide dismutase. In
Huntington’s disease the means by which the nuclear
DNA encoded expansion of CAG repeats in hunting-
tin results in mitochondrial dysfunction remain to be
clari¢ed, yet increasing evidence implicates an im-
pairment of bioenergetics in Huntington pathogene-
sis.
2. Alzheimer’s disease
Alzheimer’s disease (AD) is the most common of
the neurodegenerative diseases. The most important
risk factor is advancing age [1]. The illness occurs in
both a familial form which is autosomal dominant
inherited and an apparently sporadic illness. Familial
autosomal dominant Alzheimer’s disease is associ-
ated with point mutations in the amyloid precursor
protein as well as in novel proteins entitled preseni-
lin-1 and presenilin-2. Familial Alzheimer’s disease
accounts for approximately 5% of all cases. The re-
maining apparently sporadic cases of Alzheimer’s
disease show an increased risk in families of 2.5^3-
fold. A sporadic inheritance pattern with familial as-
sociation and evidence for maternal transmission are
characteristic features of known mitochondrial genet-
ic diseases. Some evidence has suggested that there is
maternal inheritance in Alzheimer’s disease [2,3].
These studies showed an increase in female to male
ratio in the parental generation of Alzheimer’s dis-
ease probands. In a group of families in which there
were both an a¡ected parent and at least two a¡ected
siblings the ratio of mothers to fathers in the paren-
tal generation was 9:1 [2].
There is substantial evidence implicating metabolic
defects in Alzheimer’s disease. Studies utilizing posi-
tron emission tomography consistently show reduced
glucose metabolism in temporoparietal regions of
Alzheimer’s disease patients, and this appears to oc-
cur quite early in the disease course [4]. Recent stud-
ies have demonstrated that this occurs in patients at
risk for Alzheimer’s disease [5], and there appeared
to be reduced glucose utilization in asymptomatic
patients who are homozygous for the Apo O4 allele,
a known risk factor for sporadic Alzheimer’s disease
[6]. Positron emission tomography studies also show
increased oxygen utilization in comparison with glu-
cose utilization in Alzheimer’s disease patients [7].
This latter observation has been con¢rmed with di-
rect measurements in arterial and jugular venous
samples [8,9]. Prior work also demonstrated abnor-
mal glucose metabolism in brain biopsy specimens
[10]. Phosphorus magnetic resonance spectroscopy
has demonstrated abnormalities in either phospho-
creatine (PCr) or inorganic phosphate (Pi) in Alz-
heimer’s disease patients as compared with elderly
controls [11,12]. The study of Smith and colleagues
demonstrated a reduction in PCr/Pi ratio in the fron-
tal cortex of Alzheimer’s disease patients [13].
Initial studies which suggested that there were de-
fects in cytochrome oxidase in Alzheimer’s disease
were done in platelets. Parker and colleagues re-
ported signi¢cant decreases in cytochrome oxidase
activity in Alzheimer’s disease platelets as compared
to normal controls [14]. This work was disputed uti-
lizing less puri¢ed platelets preparations but was con-
¢rmed in a follow-up study [15,16]. Studies of post-
mortem cerebral tissue of Alzheimer’s disease
patients con¢rmed reduced cytochrome oxidase ac-
tivity [17,18]. The cytochrome oxidase activity shows
a reduction in catalytic activity yet normal amounts
of cytochrome aa3, suggesting that reduced complex
IV activity is a consequence of abnormal catalytic
activity rather than decreased enzyme levels [16].
Although prior biochemical studies suggested that
there were decreases in cytochrome oxidase activity
in Alzheimer’s disease platelets and cerebral tissue, it
was unclear whether this was a primary or secondary
e¡ect of the disease process. A novel technique to
investigate the role mitochondrial defects is to utilize
cybrid technology, which was pioneered by King and
Attardi [19]. This technique involves the transfer of
mitochondria from living patients or cell lines to mi-
tochondria de¢cient cells (b0 cells). Cell lines from a
variety of sources can be depleted of mitochondrial
DNA (mtDNA) by exposing them to low concentra-
tions of ethidium bromide. Ethidium bromide is con-
centrated within mitochondria and preferentially in-
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hibits mtDNA replication in comparison to nuclear
DNA replication. Exposed cells lose their mtDNA
and assume an anaerobic phenotype. Cybrids are
cells formed by fusing mitochondria from platelets
or other tissues into the b0 cells. Since the b0 cells
are auxotrophic for uridine and pyruvate, any cells
which are not transformed are then eliminated by
removing uridine and pyruvate from the medium.
The resulting cybrids then enable one to determine
whether any observed defects in oxidative phospho-
rylation are attributable to alterations in the patient’s
mtDNA, since the patient’s mitochondria now func-
tion in the presence of a di¡erent nuclear back-
ground.
Recent studies using the cybrid technique to dem-
onstrated that the cytochrome oxidase defects in Alz-
heimer’s disease appear to be encoded on mtDNA
[20,21]. It was shown that cytochrome oxidase de-
fects can be transferred from Alzheimer’s disease
platelets into cybrids. Furthermore the ensuing
cybrid cell lines show markedly increased free radical
production. Point mutations were found in the cyto-
chrome oxidase-1 and cytochrome oxidase-2 mtDNA
encoded subunits of cytochrome oxidase, however
further work needs to be done to exclude the possi-
bility that these mutations are not present in nuclear
pseudogenes. Nuclear pseudogenes are mitochondrial
DNA sequences which are randomly incorporated
into the nuclear genome by unclear mechanisms,
but which exist for much of the mitochondrial ge-
nome.
The consequences of cytochrome oxidase defects in
cybrid cell lines on intracellular calcium bu¡ering
have been determined [22]. The Alzheimer’s disease
cybrids show elevated basal cytosolic calcium con-
centrations as well as enhanced sensitivity to inosi-
tol-1,4,5-triphosphate mediated calcium release. They
also show slower recovery from the increased calci-
um levels. These ¢ndings are consistent with prior
observations in AD ¢broblasts [23^25]. They are
also consistent with the ¢nding of decreased calcium
uptake in mitochondria from AD ¢broblasts [26].
Impaired calcium bu¡ering is also known to occur
in ¢broblasts of patients with a known mitochondrial
disorder, MELAS syndrome [27].
Alzheimer’s disease cybrid cell lines are associated
with increased free radical production. One therefore
might expect that there would be evidence for in-
creased free radical damage in Alzheimer’s disease
postmortem tissue. Mitochondrial DNA may be
preferentially vulnerable since it is located close to
the inner mitochondrial membrane. Consistent with
this possibility we found a 3-fold increase in 8-hy-
droxy-2-deoxyguanosine content of mtDNA in AD
postmortem tissue as compared to age-matched con-
trols [28]. In other studies there have been reports of
increased tissue concentrations of malondialdehyde
and protein carbonyl groups [29,30]. Furthermore
novel spin trapping techniques demonstrated in-
creased oxidative damage to both lipids and proteins
[31]. Immunocytochemical studies have demon-
strated that there is evidence for oxidative damage
at the cellular level. Neuro¢brillary tangle bearing
neurons showed increased immunostaining with anti-
bodies to advanced glycation end products, hemeox-
ygenase-1, malondialdehyde, 4-hydroxynonenal, pro-
tein carbonyl groups, carbonylated neuro¢laments,
and 3-nitrotyrosine [13,32^38]. Interestingly these
antibodies show increased staining in cell bodies
and neurites rather than in senile plaques, suggesting
an intracellular source of free radicals.
Mitochondrial dysfunction may be linked to the
other neuropathological hallmarks of Alzheimer’s
disease including senile plaques and neuro¢brillary
tangles. Previous studies showed that impairment of
cytochrome oxidase in vitro leads to an increase in
C-terminal fragments of the amyloid precursor pro-
tein, which contain the L-amyloid peptide [39], and a
decrease in non-amyloidogenic processing of the
amyloid precursor protein [40]. An increase in intra-
cellular L-amyloid 1^42 was found after exposure of
cultured guinea pig neurons to hydrogen peroxide,
and oxidative stress increased L-amyloid in mamma-
lian lens tissue [41,42]. An increase in intracellular L-
amyloid was also observed in cultured astrocytes
from Down syndrome patients in which there is in-
creased free radical production [43]. Oxidative dam-
age may lead to cross-linking and impaired solubility
of L-amyloid [44,45].
Oxidative injury has also been shown to lead to
intermolecular cross links in covalent bonds which
could contribute to the generation of paired helical
¢laments [46]. Oxidation of critical cysteine residues
seems to be associated with the aggregation of tau
proteins into paired helical ¢laments [47]. Reduced
ATP generation also leads to activation of ERK1
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and ERK2 kinases which phosphorylate tau proteins
into a paired helical ¢lament-like state similar to that
in AD [48,49].
3. Friedreich’s ataxia
A role of mitochondrial dysfunction in Fried-
reich’s ataxia has been greatly strengthened by recent
observations. Friedreich’s ataxia is characterized by
neurodegeneration involving the spinocerebellar
pathways as well as a cardiomyopathy. The gene
product was recently cloned and designated frataxin
[50]. Frataxin de¢ciency may be a consequence of
nonsense or missense point mutations, but the pri-
mary cause appears to be an expansion of a poly-
morphic GAA trinucleotide repeat situated in the
¢rst intron of the corresponding gene. This results
in marked reduction in steady state levels of mature
frataxin mRNA. There appears to be a correlation
between the regions of degeneration observed in the
disease and the sites of frataxin transcription, which
are highest in the heart, spinal cord and dorsal root
ganglia [51]. Recent studies show that a gene from
yeast is homologous to the human frataxin protein
[52]. This gene encodes a mitochondrial protein in-
volved in iron homeostasis and respiration function.
Human frataxin has been linked to green £uorescent
protein and was shown to be localized to mitochon-
dria [51^54]. Disruption of the yeast homologous
gene results in respiratory insu⁄ciency with an in-
ability to carry out oxidative phosphorylation
[51,52,54], as well as a loss of mitochondrial DNA
[52,54]. Yeast with disruption of their frataxin homo-
logue show marked increases in iron transport, in-
creases in iron content, and hypersensitivity to oxi-
dative stress mediated by H2O2 [52]. These
observations suggest that impaired function of this
protein most likely leads to mitochondrial dysfunc-
tion and results in hypersensitivity to oxidative stress,
presumably mediated by iron catalyzed Fenton
chemistry. This speculation is supported by studies
of endomyocardial biopsies of patients with Fried-
reich’s ataxia [55]. The biopsies show de¢ciencies of
aconitase and complexes I, II and III of the electron
transport chains which contain iron-sulfur clusters
and are known to be susceptible to oxidative stress.
It is also of interest that a Friedreich’s ataxia-like
syndrome with retinitis pigmentosis is caused by mu-
tations in the K-tocopherol transfer protein [56^58].
This results in reduced concentrations of vitamin E.
Neurological symptoms in this disorder include atax-
ia, dysarthria, hypore£exia and decreased proprio-
ceptive sensation.
Other evidence implicating mitochondrial dysfunc-
tion in Friedreich’s ataxia includes an increased in-
cidence of diabetes mellitus and optic atrophy which
are frequent complications of mitochondrial disor-
ders. Positron emission tomography studies of Fried-
reich’s ataxia patients have detected cerebral glucose
hypermetabolism early in disease progression [59].
Biochemical studies found increased blood lactate
levels and generally abnormal carbohydrate metabo-
lism in patients with Friedreich’s ataxia [60]. Re-
duced activities of several mitochondrial enzymes in-
cluding K-ketoglutarate dehydrogenase and pyruvate
dehydrogenase have also been reported [61].
4. Amyotrophic lateral sclerosis (ALS)
Amyotrophic lateral sclerosis (ALS) is a prototyp-
ical neurodegenerative disease of late life character-
ized by progressive muscle weakness, atrophy and
spasticity [62]. It leads to paralysis and death within
3^5 years after onset. Characteristic neuropathologic
features are loss of anterior horn motor neurons as
well as degeneration of the corticospinal tracts.
Ninety percent of ALS cases are apparently sporadic
with no identi¢able genetic or environmental risk
factors. The remaining 10% of cases show familial
autosomal dominant inheritance. A major advance
in the understanding of ALS was the identi¢cation
of point mutations in the enzyme superoxide dismu-
tase in approximately 25% of patients who have fam-
ilial ALS [63]. More than 60 mutations have now
been associated with the disease. These mutations
typically a¡ect the protein backbone of the enzyme
and may interfere with normal dimer interactions.
Only two mutations have thus far been reported
which may a¡ect the active site copper.
The observation that mutations in superoxide dis-
mutase cause familial ALS suggested that oxidative
injury might be playing role in its pathogenesis.
Although there is a decrease in superoxide dismutase
activity in familial ALS patients, strong evidence sug-
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gests that the genetic defect leads to a gain of func-
tion from the mutant enzyme. This evidence includes
the dominant inheritance pattern of familial ALS,
the lack of correlation between enzyme activity and
disease severity [64], and the observation that over-
expression of the mutant enzyme in transgenic mice
leads to motor neuron degeneration [65^67]. The mu-
tations appear to alter the stability of the protein
backbone and reduce the half-life of the molecule
[68]. They also appear to alter zinc binding [69].
These changes may relax the conformation of the
active channel thereby allowing increased access of
hydrogen peroxide or peroxynitrite to the active site
copper. This is predicted to increase generation of
hydroxyl radicals or nitronium ions which can then
nitrate proteins [70]. In support of this two in vitro
studies showed that superoxide dismutase with two
di¡erent familial ALS mutations can generate in-
creased amounts of hydroxyl radicals as compared
to wild-type molecules [71^73]. Furthermore we re-
cently obtained evidence in two di¡erent strains of
transgenic ALS mice that there are increases in 3-
nitrotyrosine concentrations, consistent with in-
creased accessibility of peroxynitrite to the active
site copper [74,75]. Of interest in both of these lines
of transgenic ALS mice mitochondrial vacuolization
and swelling are prominent pathologic features
[65,67]. Furthermore we found increased complex I
activity in both postmortem brain material of pa-
tients with the A4V superoxide dismutase mutation
as well as in transgenic mice with the G93A super-
oxide dismutase mutation [76]. It is possible that in-
creased generation of free radicals may damage the
inner mitochondrial membrane. This could lead to a
proton leak which would therefore have to be com-
pensated by increased activity of the mitochondrial
electron transport complexes responsible for proton
transport. Expression of superoxide dismutase with
the G93A mutation in neuroblastoma cells in vitro
leads to a loss of mitochondrial membrane potential
and increases in cytosolic calcium [77].
In sporadic ALS there is also evidence to suggest
impairment of energy metabolism. Reduced glucose
metabolism has been observed in cerebral cortex as
sporadic ALS patients using positron emission to-
mography [78,79]. We recently examined electron
transport enzymes in postmortem tissue of sporadic
ALS patients. No alterations were found but this
could be due to heterogeneity of defects amongst
patients, which would obscure them due to an aver-
aging e¡ect [76]. Furthermore abnormalities could be
obscured by astrogliosis. A recent study using the
cybrid cell technique showed that there appeared to
be mild decreases in complex I and complex IV ac-
tivities associated with sporadic ALS [80]. Further-
more peripheral blood lymphocytes from sporadic
ALS patients show increased cytosolic calcium and
impaired responses to uncouplers of oxidative phos-
phorylation [81]. Studies of motor neurons in spo-
radic ALS patients show an accumulation of mito-
chondria in proximal axons, and muscle biopsies
show increased mitochondrial volume and calcium
levels [82^84]. Liver biopsies show enlarged mito-
chondria with intramitochondrial inclusions in
sporadic ALS patients [85]. Mitochondria with ab-
normal protrusions were observed in anterior horn
cells of a familial ALS patient who was later deter-
mined to have a superoxide dismutase mutation [86].
A consequence of mitochondrial dysfunction in
either familial or sporadic ALS patients may be in-
creased oxidative damage. Both we and others have
observed increased protein carbonyl groups in the
motor cortex and spinal cord of ALS patients
[76,87]. We recently found increased concentrations
of 3-nitrotyrosine and its major metabolite 3-nitro-4-
hydroxyphenylacetic acid in the thoracic and lumbar
spinal cord of both sporadic and familial ALS pa-
tients [88]. Immunocytochemical staining also dem-
onstrated increased 3-nitrotyrosine in anterior horn
cells.
A pathologic hallmark of familial and sporadic
ALS is the accumulation of neuro¢laments in prox-
imal axons [89,90]. This may be a consequence of
oxidative damage or it could be due to accumulation
of 3-nitrotyrosine in the neuro¢lament light chain
[70], which impairs normal aggregation of neuro¢la-
ments [91,92]. Furthermore an energy defect may
contribute to slowing to axonal transport which
has recently been demonstrated in sporadic ALS pa-
tients, in which there was an accumulation of mito-
chondria in proximal axons [83].
5. Huntington’s disease
The genetic defect in Huntington’s disease (HD)
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consists of an expanded CAG repeat in a gene lo-
cated on chromosome 4. The gene encodes a novel
protein designated huntingtin which is widely distrib-
uted in both the peripheral tissues of the body as well
as in the central nervous system. Both the normal
function of huntingtin as well as its role in the patho-
genesis of neuronal degeneration in Huntington’s dis-
ease are obscure. Substantial evidence however sug-
gests that the disease mutation leads to a gain of
function causing cell type speci¢c neuronal degener-
ation predominantly in the striatum. Evidence in
support of this includes the observation that hetero-
zygote knockout mice of the gene huntingtin do not
show any phenotypic abnormalities [93]. The cleav-
age of huntingtin leads to N-terminal fragments
which aggregate to form intranuclear inclusion
bodies and aggregates in dystrophic neurites [94].
There is a substantial body of evidence implicating
defects in energy metabolism in HD. Decreased glu-
cose metabolism using positron emission tomogra-
phy has been consistently shown in HD patients.
The reductions in glucose metabolism occur in pre-
symptomatic patients [29]. Furthermore we utilized
proton magnetic resonance spectroscopy to demon-
strate that there are elevated lactate concentrations
in both the occipital cortex and in the basal ganglia
of HD patients [95]. Increased lactate concentrations
occur in the basal ganglia of some but not all pre-
symptomatic patients, suggesting that the metabolic
defects can precede clinical manifestations of the ill-
ness. Other authors found increased lactate in both
frontal cortex as well as in occipital cortex and cer-
ebellum [96,97]. We observed increased lactate con-
centrations in both parietal and supplementary mo-
tor cortex, suggesting that there is a widespread
metabolic defect in Huntington’s disease brain tissue.
Furthermore we found a decrease in PCr/Pi ratio in
resting gastrocnemius muscle of HD patients, provid-
ing evidence that there are defects in energy metab-
olism in peripheral tissues as well [98]. The latter
observation is consistent with reports of progressive
weight loss in HD patients despite increased caloric
intake [99]. Furthermore we found that cerebrospinal
£uid lactate to pyruvate ratios are increased in HD
subjects as compared to age-matched controls, and
similar observations have been made in patients with
Machado-Joseph disease which is also due to an ex-
pansion of CAG repeats [98,100].
Reports of changes in enzymes involved in oxida-
tive phosphorylation have shown reduced succinate
dehydrogenase activity in HD postmortem brain tis-
sue [101,102]. Reports of mitochondrial electron
transport enzymes yielded inconsistent results. Two
recent studies however demonstrated a 55^60% de-
crease in complex II^III activity in Huntington’s dis-
ease basal ganglia [103,104]. Smaller decreases in cy-
tochrome oxidase activity were less consistent.
Complex I and citrate synthase activity showed no
changes. The most consistent alterations in electron
transport activity therefore appear to be decreases in
complex II^III activity in the basal ganglia of HD
patients. This is of interest since genetic defects af-
fecting complex II^III activity are associated with
basal ganglia degeneration [105], and comparable de-
fects in experimental animals result in striatal degen-
eration [106]. Studies in cultured ¢broblasts from
HD and control patients also show mitochondrial
defects [107]. Ionomycin induced calcium in£uxes re-
sult in depolarization of the mitochondrial mem-
brane potential. Normal ¢broblasts show depolariza-
tion followed by recovery, but Huntington’s disease
¢broblasts show failure to recovery fully after the
second application of ionomycin.
One proposed mechanism by which the HD gene
defect could lead to impaired energy metabolism is
by an interaction between huntingtin and glyceralde-
hyde-3-phosphate dehydrogenase, a critical compo-
nent of the glycolytic pathway [108]. It was suggested
that an increase in polyglutamine repeats in hunting-
tin potentially inhibits the enzyme. Indeed we found
that intrastriatal administration of the glyceralde-
hyde-3-phosphate dehydrogenase inhibitor iodoace-
tate produces dose dependent striatal lesions, which
correlate with inhibition of enzyme activity [109].
However we could not con¢rm a decrease in glycer-
aldehyde-3-phosphate dehydrogenase activity in
postmortem brain tissue of Huntington’s disease pa-
tients [104], however a competitive inhibition could
still occur. There is limited evidence for oxidative
damage postmortem brain tissue of Huntington’s dis-
ease patients. We found increased concentrations of
8-hydroxy-2-deoxyguanosine in nuclear DNA in
Huntington’s disease caudate [104]. Furthermore
our initial immunocytochemical studies showed in-
creased staining of striatal neurons of HD patients
with antibodies to hemeoxygenase-1, 8-hydroxy-2-de-
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oxyguanosine and malondialdehyde modi¢ed protein
[110].
Other evidence implicating mitochondrial dysfunc-
tion in the pathogenesis of Huntington’s disease
comes from studies of mitochondrial toxins. We uti-
lized 3-nitropropionic acid, an irreversible inhibitor
of succinate dehydrogenase, to attempt to model
Huntington’s disease in both rodents and primates
[106,111]. Accidental ingestion of 3-nitropropionic
acid in man produces selective basal ganglia lesions
and dystonia [112]. Systemic administration of 3-ni-
tropropionic acid to nonhuman primates results in
both a movement disorder as well as frontal type
cognitive de¢cits which are similar to those which
occur in HD [106,113]. Histological evaluation
showed basal ganglia degeneration with sparing of
NADPH diaphorase interneurons, dendritic abnor-
malities in spiny neurons and sparing of the nucleus
accumbens, all of which are characteristic features of
Huntington’s disease neuropathology.
Further evidence for a metabolic defect in HD
comes from a recent transgenic animal model [114].
Transgenic mice were made expressing a large num-
ber of CAG repeats (130^140) in exon 1 of the HD
gene. These mice developed normally for about
8 weeks followed by onset of a movement disorder
with tremors and subsequent seizures. The mice die
at approximately 12^14 weeks of age. Intranuclear
inclusion bodies which stain with N-terminal anti-
bodies to huntingtin develop preceding the onset of
symptoms [20]. It has therefore been suggested that
these nuclear inclusion bodies may play a role in
disease pathogenesis. Although there is no degener-
ation of the basal ganglia the brains appear to be
small, and this occurs early in the disease process.
A characteristic feature of these mice is progressive
weight loss despite increased caloric intake [114].
These ¢ndings are consistent with those observed in
Huntington’s disease patients who also appear to
have increased caloric intake despite weight loss
[99]. These ¢ndings therefore suggest that there
may indeed be a metabolic defect in both a trans-
genic animal model of HD as well as in patients.
Furthermore we have recently studied another trans-
genic animal model of HD in which there is a ex-
pansion of either 48 or 66 repeats in the full length
huntingtin protein (Browne et al., unpublished ¢nd-
ings). These mice as yet have not shown any pheno-
typic abnormalities. The mice however show in-
creased 2-deoxyglucose uptake in the basal ganglia,
further suggesting a metabolic defect associated with
the CAG expansion in the huntingtin protein.
6. Therapeutic strategies
If a defect in energy metabolism underlies the
pathogenesis of neurodegenerative diseases then a
reasonable therapeutic strategy is to utilize com-
pounds which improve mitochondrial function.
Coenzyme Q10 or ubiquinone is an essential compo-
nent of the electron transport chain where it serves as
an electron donor and acceptor. It is also a potent
antioxidant, particularly in mitochondria. Prior work
demonstrated that it protects against glutamate tox-
icity in cultured cerebellar neurons [115]. We demon-
strated that it produces dose-dependent protection
against striatal lesions produced by the succinate de-
hydrogenase inhibitor malonate [111]. More recently
we found that it produces marked neuroprotection
against 3-nitropropionic acid toxicity, and also im-
proves survival in a transgenic animal model of ALS
associated with point mutations and superoxide dis-
mutase (Beal et al., unpublished data). It protects
against malonate ATP depletions [111], and it pro-
tects against MPTP induced dopamine depletions in
older mice [116]. Examination of its e¡ects in HD
patients show that it produced a signi¢cant 36% de-
crease in occipital cortex lactate concentrations as
assessed by magnetic resonance spectroscopy [98].
Following withdrawal of the coenzyme Q10 treatment
the lactate levels return to baseline. It produced ad-
ditive e¡ects with the N-methyl-D-aspartate (NMDA)
antagonist MK-801 against malonate toxicity in vivo
[117]. In view of these neuroprotective e¡ects a clin-
ical trial has been designed to assess the e¡ects of
coenzyme Q10 with or without an NMDA antagonist
in the treatment of Huntington’s disease patients.
Another novel therapeutic strategy to ameliorate
mitochondrial induced dysfunction is to attempt to
bu¡er intracellular energy stores. The major energy
source in the brain is ATP which is tightly coupled to
phosphocreatine. A therapeutic strategy may there-
fore be to administer creatine to attempt to increase
phosphocreatine and ATP concentrations within the
brain. Creatine kinase catalyzes the reaction of ATP
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with phosphocreatine to generate ATP [118]. ATP
generated by oxidative phosphorylation is trans-
ported through the mitochondrial inner membrane
by the adenine nucleotide transporter, where it is
transphosphorylated with creatine by the mitochon-
drial creatine kinase to generate phosphocreatine.
Phosphocreatine then leaves the mitochondria and
di¡uses to the cytoplasm where it serves as both a
temporal and spatial energy bu¡er. Phosphocreatine
maintains ATP levels utilized by the sodium potas-
sium ATPase and the calcium ATPase [119]. It serves
to maintain membrane potential and to restore ion
gradients after neurotransmitter release, consistent
with the localization of high amounts of creatine
kinase to brain regions rich in synaptic connections
[120]. Its importance to brain function is supported
by in vivo 31P NMR transfer measurements showing
a correlation of creatine kinase £ux with brain activ-
ity measured by the EEG as well as with brain 2-
deoxyglucose uptake [121,122].
Oral administration of creatine stimulates mito-
chondrial respiration and phosphocreatine synthesis
which may help sustain ATP levels under stress con-
ditions [123]. Furthermore phosphocreatine serves as
a direct energy source for glutamate uptake into syn-
aptic vesicles [124]. We found that administration of
creatine in the diet produced signi¢cant protection
against both malonate and 3-nitropropionic acid in-
duced neurotoxicity [125]. Creatine increased brain
levels of phosphocreatine and ATP and protected
against 3-nitropropionic acid induced depletions.
Creatine also protected against 3-nitropropionic
acid induced increases in striatal lactate concentra-
tions as assessed by proton magnetic resonance spec-
troscopy. Furthermore creatine administration pro-
tected against malonate induced increases in
hydroxyl radical generation and increases in 3-nitro-
tyrosine, and 3-nitropropionic acid induced increases
in 3-nitrotyrosine, which may be a downstream con-
sequence of energy impairment. These observations
suggest that creatine administration may be a novel
therapeutic strategy for the treatment of neurode-
generative diseases.
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